Clinical Trials on Floppy Eyelid Syndrome

Total 36701 results

University of Michigan

Completed

Flomax Study for Floppy Iris Syndrome

Floppy Iris Syndrome

United States
Samsung Medical Center

Completed

Intraoperative Floppy Iris Syndrome in Korean Patients Taking α1-Adrenergic Receptor Antagonists

Intraoperative Floppy Iris Syndrome
Penn State University

Terminated

Retrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome

Intraoperative Floppy Iris Syndrome

United States
Omeros Corporation

Terminated

Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery

Intraocular Lens Replacement | Intraoperative Floppy Iris Syndrome

Austria, Germany
Alcon Research

Completed

Intraoperative Floppy Iris Syndrome

Cataract | Floppy Iris Syndrome

United States
Meir Medical Center

Unknown

The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients

Intraoperative Floppy Iris Syndrome

Israel
University of California, San Francisco

Unknown

Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery

Eyelid Diseases | Ptosis, Eyelid | Blepharoptosis | Eyelid Tumor | Dermatochalasis | Entropion | Ectropion | Skin Cancer, Eyelid | Floppy Eyelid Syndrome

United States
Assiut University

Not yet recruiting

Patterns Of Floppy Infants Attending Assiut University Children Hospital

Floppy Infant
Universidad de Murcia

Completed

Assessment of Hypotonia in Children With Down Syndrome

Down Syndrome | Muscle Hypotonia | CHILD Syndrome | Infant Floppy | Muscle, Floppy

Spain
Denver Health and Hospital Authority

Completed

Pupil Dilation for Treatment of IFIS

Intraoperative Floppy Iris Syndrome

United States
Meir Medical Center

Completed

Use of APX 100 Device for Small-pupil Cataract Surgery and Intraoperative Floppy-iris Syndrome

Intraoperative Floppy Iris Syndrome | Miosis Disorder

Israel
University Hospital Olomouc
Palacky University

Completed

Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome

Cataract | Age-related Cataract | Intraoperative Floppy Iris Syndrome | Adrenergic Receptor Antagonist Adverse Reaction

Czechia
Vienna Institute for Research in Ocular Surgery

Unknown

Methods to Manage Intra-operative Floppy-iris Syndrome and Poor Pupil Dilation in Cataract Surgery (IFIS)

Management of Intraoperative Floppy-iris Syndrome and Small Pupils With Different Mechanical Devices

Austria
University Hospital Ostrava

Recruiting

Objective Evaluation of the Effect of Oculoplastic Operations Using the Vectra M 3D Imaging System

Eyelid Ptoses | Ectropion Eyelids | Entropion;Eye

Czechia
Assiut University

Unknown

Causes of Peripheral Hypotonia in Assiut University Children Hospital

Infant Floppy
TJ Biopharma Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndromes(MDS)

China
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Celgene Corporation

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (Aza-E)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Australia
Maria Sklodowska-Curie National Research Institute...
KCRI

Not yet recruiting

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes (CLARA)

Acute Myeloid Leukemia Myelodysplastic Syndromes

Poland
Olympic Ophthalmics, Inc.

Recruiting

A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation

MicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye Syndrome

United States
City of Hope Medical Center

Completed

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndromes

United States
The University of Hong Kong

Recruiting

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

Dry Eye Syndromes | Meibomian Gland Dysfunction

Hong Kong
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Stanford University
Celgene Corporation

Terminated

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Leukemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Washington University School of Medicine
Cephalon

Completed

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Myelodysplastic Syndromes and Leukemia, Myeloid, Acute

United States
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
Centre Hospitalier Universitaire de Saint Etienne
Quantel Medical

Completed

Intense Pulsed Light in Meibomian Gland Dysfunctions (LACRYSTIM)

Dry Eye Syndromes | Meibomian Gland Dysfunction

France
TearScience, Inc.

Completed

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

Dry Eye Syndromes | Chalazion

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Franziska Wachter
Harvard Clinical and Translational Science Center (Harvard Catalyst)

Recruiting

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies (MORE)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure Syndrome

United States
Remix Therapeutics

Not yet recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
Aston University

Not yet recruiting

Photobiomodulation With REd vs BluE Light (REBEL)

Dry Eye Syndromes | Meibomian Gland Dysfunction | Blepharitis

United Kingdom
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Hackensack Meridian Health

Terminated

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)

Acute Myeloid Leukemia and Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.; Forma Therapeutics, Inc.

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

China
Shandong Provincial Hospital

Unknown

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Myelodysplastic Syndromes,Acute Myeloid Leukemia

China
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
University of Ulm

Terminated

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Germany
Cornerstone Pharmaceuticals

Withdrawn

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
Viron Therapeutics Inc
Vion Pharmaceuticals

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Cardiff University
Experimental Cancer Medicine Centres; Leukaemia & Lymphoma Research Group

Completed

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)

High Risk Myelodysplastic Syndrome | Acute Myeloid Leukaemia

United Kingdom
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia and Myelodysplastic Syndrome

China
AbbVie

Terminated

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Australia, Germany, Israel, Italy, Japan, Spain
University of Washington
National Cancer Institute (NCI)

Completed

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia | Adult Myelodysplastic Syndrome

United States
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Canada, United Kingdom
University of California, San Francisco
Novartis

Completed

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndrome

United States

Clinical Trials on Floppy Eyelid Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations